Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kathryn Kelly

Internal Medicine Silver Spring, MD Medical Doctor

NPI 1649447228 CMS profile 255891

10801 Lockwood Dr, Suite 210, Silver Spring, MD 20901

Open in the dashboard

General payments

$2,896

136 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$530,575 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Kathryn Kelly of Silver Spring, MD is reported in the CMS Open Payments database as having received $2,896 across 136 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $530,575 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $644 24
2024 General $31 2
2023 General $343 17
2022 General $249 11
2021 General $366 17
2020 General $690 39
2019 General $574 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Kelly
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kathryn Kelly were reported at $644. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kathryn Kelly Internal Medicine median Middle half National median
2019 $574 $159 $48–$570 $163
2020 $690 $119 $33–$402 $114
2021 $366 $135 $37–$521 $132
2022 $249 $141 $42–$496 $149
2023 $343 $149 $45–$519 $160
2024 $31 $154 $47–$537 $164
2025 $644 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $588 20 payments
  2. AbbVie, Inc. $481 21 payments
  3. Pfizer Inc. $248 15 payments
  4. Lilly USA, LLC $211 11 payments
  5. Allergan Inc. $177 13 payments
  6. Gilead Sciences, Inc. $160 7 payments
  7. AstraZeneca Pharmaceuticals LP $149 8 payments
  8. Genzyme Corporation $130 2 payments
  9. Biohaven Pharmaceuticals, Inc. $67 3 payments
  10. Eisai Inc. $62 4 payments
  11. Other $623 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,896 136 payments
Products named General payments · program years 2019–2025
  1. Ozempic $337 12 payments
  2. UBRELVY Neuroscience $336 15 payments
  3. RYBELSUS $206 8 payments
  4. QULIPTA $191 8 payments
  5. Tresiba $142 5 payments
  6. ELIQUIS $125 8 payments
  7. FARXIGA $109 6 payments
  8. JARDIANCE $100 5 payments
  9. UBRELVY Neuroscience $99 6 payments
  10. LINZESS $87 5 payments
  11. Other $1,663 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

3,950

Median for Internal Medicine: 777

Drug cost

$334,072

Median for Internal Medicine: $73,373

Branded share of claims

20.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 42 $53,995
Mounjaro Tirzepatide Brand 19 $40,881
Jardiance Empagliflozin Brand 32 $38,687
Eliquis Apixaban Brand 40 $34,077
Januvia Sitagliptin Phosphate Brand 17 $20,417
Trulicity Dulaglutide Brand 15 $16,571
Linzess Linaclotide Brand 19 $16,256
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $15,028
Tresiba Flextouch U-100 Insulin Degludec Brand 27 $12,943
Janumet Sitagliptin Phos/Metformin Hcl Brand 11 $7,082

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$95,625

Of which drugs: $2,832

Medicare patients

306

Average age 71

Services billed

2,129

241 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Diabetes 37%
Depression 19%
Chronic kidney disease 18%
Ischemic heart disease 15%
Osteoporosis 13%
Cancer 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $26
$26 19 —
ELIQUIS
  • PFIZER INC. $2
$2 40 —
NURTEC ODT
  • PFIZER INC. $2
$2 — —
PAXLOVID
  • PFIZER INC. $2
$2 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

136 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record